首发症状为颌下腺肿大的Castleman病超声表现1例

2019-05-07 蒋南 薛丹 中国超声医学杂志

患者男,49岁。自述双侧颌下肿大2个月余,无红肿、疼痛等不适,近一周感觉肿大明显来我院检查。有轻微盗汗,偶伴胸闷、气短及口干。查体:双侧颌下均可触及一包块,表面不光滑,无压痛。双颈部、腋下及腹股沟可触及多个淋巴结,质韧,表面光滑,无压痛,活动度尚可。

患者男,49岁。自述双侧颌下肿大2个月余,无红肿、疼痛等不适,近一周感觉肿大明显来我院检查。有轻微盗汗,偶伴胸闷、气短及口干。查体:双侧颌下均可触及一包块,表面不光滑,无压痛。双颈部、腋下及腹股沟可触及多个淋巴结,质韧,表面光滑,无压痛,活动度尚可。
 
超声检查:双侧颌下腺体积明显增大,内部回声不均,内见网格状强回声,腺体内血流信号丰富(图1a);双侧颈部、腋下及腹股沟见多个肿大淋巴结,大者位于右侧腋下243mm×17.9mm,包膜清晰,类圆形,淋巴门未显示,中央及周边见少量点条状血流(图1b)。超声提示:(1)双侧颌下腺增大伴回声异常,不除外干燥综合征;(2)全身多发淋巴结肿大,建议进一步检查。胸腹增强CT:纵隔见多发增大淋巴结影,大者直径22mm,增强后见强化。
 


免疫组化:(右侧腋下淋巴结)CD68(散在+),CD3(T细胞+),CD21(生发中心+),CD20(B细胞+),Ki-67(30%+),CD10(一)。病理结论:(右侧腋下淋巴结)淋巴结增生病变,考虑为Castleman病(多中心型、细胞质型)(图2)。
 


讨论
 
Castleman病(Castleman disease,CD)为病理与淋巴瘤极相似的非典型淋巴组织增值性疾病,又称为巨大淋巴结增生症或血管滤泡性淋巴组织增生,这与患者多表现为巨大淋巴结增生症或血管滤泡性淋巴组织增生有关。成人病例多见,其发病原因及机制上尚无明确定论,部分学者认为该病的发生或与人类疱疹病毒8型(HHV8)感染机体和白细胞介素(IL-6)分泌异常有关。CD发病率低,临床表现多样且实验室检查无特异度,故依靠病理学检查进行诊断
 
本病分为局灶性和多中心型两个亚型,后者预后差,少数多中心型可进展为恶性淋巴瘤。有文献报道CD在疾病进展时可累及泪腺和颌下腺,笔者在行本例超声检查时,受到患者口干症状的影响,仅考虑干燥综合征,未将颌下腺改变与浅表淋巴结肿大相联系。另本病淋巴结声像图应与淋巴瘤相鉴别,淋巴瘤呈树枝状门样丰富血流信号,而CD淋巴结内门样血流不明显,内呈短条状,周边环形血流。笔者认为,超声医师应掌握Castleman病临床表现,在今后的工作中灵活思考,尽量避免误诊、漏诊,为临床诊治提供参考。
 
原始出处:

蒋南,薛丹.首发症状为颌下腺肿大的Castleman病超声表现1例[J].中国超声医学杂志,2018(03):289.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2019-05-09 fengyi812
  5. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]
    2019-05-09 yaanren
  7. [GetPortalCommentsPageByObjectIdResponse(id=2018275, encodeId=eb5c20182e583, content=<a href='/topic/show?id=774710131682' target=_blank style='color:#2F92EE;'>#首发症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101316, encryptionId=774710131682, topicName=首发症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Sat Feb 15 04:38:00 CST 2020, time=2020-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716597, encodeId=f11f1e1659739, content=<a href='/topic/show?id=56d41006816f' target=_blank style='color:#2F92EE;'>#颌下腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100681, encryptionId=56d41006816f, topicName=颌下腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3bf32257172, createdName=lvygwyt2792, createdTime=Mon Sep 02 23:38:00 CST 2019, time=2019-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711933, encodeId=1d041e11933d0, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Wed Oct 09 21:38:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317508, encodeId=2ea1131e50892, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321626, encodeId=af6e13216264c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624926, encodeId=5d12162492600, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Thu May 09 00:38:00 CST 2019, time=2019-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632674, encodeId=d79d16326e42a, content=<a href='/topic/show?id=676d92821e3' target=_blank style='color:#2F92EE;'>#超声表现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92821, encryptionId=676d92821e3, topicName=超声表现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dfe21938258, createdName=zhangjingnwpu, createdTime=Sun Jan 05 19:38:00 CST 2020, time=2020-01-05, status=1, ipAttribution=)]

相关资讯

Movement Disord:颌下腺活检有助于早期诊断帕金森病

帕金森病协会(PDF)指出,一百万名美国人患有帕金森病,每年约有6万名患者为新发病例,而成千上万名患者并未被发现。 帕金森病主要表现于老年人,但仅有4%的患者于50岁之前确定诊断。 男性患该病的几率是女性的1.5倍。 患者主要表现为退行性神经紊乱,患者的运动、睡觉、散步、平衡感、血压和嗅觉等都发生改变。该病不能治愈,但有药物可以缓解该病的表现。该病的首发和典型表现是一侧肢体的不自主颤动感(形似搓药